Protopic Phase IV Pediatric PK Studies Are Required By June 2002

Fujisawa will conduct postmarketing Protopic pediatric pharmacokinetic studies on children ages two to five following NDA approval of the topical dermatitis drug Dec. 8 for adults and children two years and older.